The Tuesday count should be more accurate.
FROM NYT (GREGG AND SMITH DON’T REPORT CASES EVERY DAY)
TWO MORE UPCOMING FREE VACCINE DAYS, ONE AT WILEY AND ONE AT TSTC
FROM BECKERS A NEW VARIANT:
The Miami hospital sees uptick in COVID-19 variant first identified in Colombia
B.1.621, a coronavirus variant first detected in Colombia, has been detected in about 10 percent of COVID-19 patients at Miami-based Jackson Health System…Frequent travel between Colombia and Miami may be responsible for the recent uptick…The strain was first identified in Colombia in January. In the U.S., B.1.621 made up about 2.1 percent of sequenced cases as of July 17, according to CDC data cited by The Washington Post. The agency has not labeled it as a variant of concern or a variant of interest…In the U.K., 16 cases of the variant have been reported, FOX reports. There, health officials consider it a “variant under investigation” and have said there’s been no indication of community transmission so far, or that the strain causes more severe illness.
1. PFIZER-BIONTECH EFFICACY/THIRD DOSE On July 28, medRxiv published preprint data from Pfizer-BioNTech showing the efficacy of its vaccine to prevent COVID-19 declined about 6% every 2 months over a period of 6 months. The data were collected from more than 40,000 clinical trial participants in Europe and the Americas. From 7 days to <2 months post-dose 2, vaccine efficacy was 96.2% (95% confidence interval [CI] 93.3-98.1); from 2 months to <4 months, efficacy was 90.1% (95% CI 86.6-92.9); and from 4 months to 6 months, efficacy was 83.7% (95% CI 74.7-89.9). Overall, vaccine efficacy was 91.1% (95% CI 88.8-93.0) for preventing symptomatic COVID-19, and 96.7% (95% CI 80.3-99.9) against severe disease. The companies said the data show the vaccine to be safe and highly efficacious in preventing COVID-19 through 6 months post-second dose in diverse populations but further data are needed to know whether efficacy continues to wane or whether “booster” doses will be necessary, and, if so, the timing of such doses.
Many experts said the not-yet-peer-reviewed data are reassuring, showing that people who are fully vaccinated likely are adequately protected. However, if the observed decline in efficacy steadily continues over time, it would fall below the internationally accepted threshold of 50% within 18 months of vaccination. This would bolster Pfizer-BioNTech’s claim that an additional shot of its vaccine will be needed to maintain long-term protection. The data also do not address the vaccine’s efficacy against the now widespread Delta variant. On July 28, Pfizer officials presented unpublished data in a quarterly earnings report to investors showing a third dose of the Pfizer-BioNTech vaccine could boost neutralizing antibody titers against the Delta variant in a small sample of individuals. The data show a more than 5-fold increase in post-second dose titers among vaccinees aged 18 to 55 and a more than 11-fold increase among those ages 65 to 85. The officials said they plan to seek authorization with the US FDA for a third dose by mid-August and indicated clinical studies of an experimental Delta variant vaccine are awaiting regulatory approval but also are expected to begin in August.
2. Pfizer Data Shows Vaccine Protection Remains Robust Six Months After Vaccination Even as the Company Argues That Boosters Will be Needed (Washington Post) On Wednesday, Pfizer published data showing that its coronavirus shots remained robustly protective six months after vaccination, providing nearly complete protection against severe disease. Pfizer’s paper, which has not yet undergone peer review, said a slight drop in efficacy against any symptomatic cases of COVID-19 from 96% protection in the first two months after vaccination to 84% after four months. Company officials also presented data showing that a third shot could boost disease-fighting antibodies many times higher than the level achieved by the standard two-dose regimen. Outside vaccine experts described the data as encouraging, even if they believe boosters will be necessary at some point for the general population and probably sooner for some groups, such as people with compromised immune systems
AND LAST BUT NOT LEASED:
FOR CHEMISTS ALCOHOL IS NOT A PROBLEM. IT’S A SOLUTION.
HAVE WE SEEN THIS ONE?
MY WIFE IS STILL HOT! IT JUST COMES IN FLASHES NOW
GIVE US YOUR FEEDBACK. CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.